TBIO Research and Charts

TBIO - Translate Bio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-13 (Delayed quote data 2025-06-27)

Last 0.10	Change ⇓ 0.00 (0.00%)	Volume 148
	Open 0.10	High 0.10	Low 0.10

8EMA (Daily) 0.07	40EMA (Daily) 0.20	50EMA (Daily) 0.24	STO (Daily) 25.000	MACD Hist (Daily) 0.035
8EMA (Weekly) 0.152	40EMA (Weekly) 1.37	50EMA (Weekly) 2.29	STO (Weekly) 3.896	MACD Hist (Weekly) 0.176


Company Profile
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.